PRAMIPEXOLE TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

可用日期:

SIVEM PHARMACEUTICALS ULC

ATC代码:

N04BC05

INN（国际名称）:

PRAMIPEXOLE

剂量:

1MG

药物剂型:

TABLET

组成:

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS

產品總結:

Active ingredient group (AIG) number: 0152169003; AHFS:

授权状态:

APPROVED

授权日期:

2018-01-09

产品特点

_ _
_PRAMIPEXOLE Product Monograph _
_Page 1 of 59_
PRODUCT MONOGRAPH
PR
PRAMIPEXOLE
Pramipexole Dihydrochloride Tablets
0.25 mg, 0.5 mg, 1 mg & 1.5 mg
pramipexole dihydrochloride monohydrate
ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent, Quebec, Canada
H4R 2P7
www.sivem.ca
Date of Revision:
November 10, 2021
Submission control No.: 257831
_ _
_PRAMIPEXOLE Product Monograph _
_Page 2 of 59_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
...................................................................................
5
ADVERSE REACTIONS
...................................................................................................
12
DRUG
INTERACTIONS....................................................................................................
21
DOSAGE AND ADMINISTRATION
...............................................................................
23
OVERDOSAGE
..................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 27
STORAGE AND STABILITY
...........................................................................................
31
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 31
PART II: SCIENTIFIC INFORMATION
..........................................................................
33
CLINICAL TRIALS
.................